Precision Medicine News and Research

RSS

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

TrovaGene, Inc. a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled "Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

13 Oct 2010

Sirius collaborates with Golden Helix to advance diagnostic pipeline

Sirius Genomics, a developer of companion diagnostics, and Golden Helix, a global leader in genetic analysis solutions, announced today a collaboration under which Golden Helix will apply its expertise and technologies in SNP and copy number variant analysis and predictive modeling to advance development of Sirius' diagnostic pipeline.

13 Oct 2010

NCI rates Abramson Cancer Center as 'exceptional'

The University of Pennsylvania's Abramson Cancer Center has been rated as "exceptional" by the National Cancer Institute (NCI) during a competitive research funding review by the government agency.

13 Oct 2010

STOA Panel schedules hearing on EU's health-related research infrastructures

On the 26 October 2010 the European Parliament's STOA (Science and Technology Options Assessment) Panel will hold a hearing entitled "Health-Related Research Infrastructures and their Contribution to the EU's Grand Challenges".

12 Oct 2010

MorphoSys and Proteros Biostructures receive research grant to develop new technology platform for structure-based engineering of antibodies

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Proteros Biostructures announced today that they have been awarded a grant by the German Federal Ministry of Education and Research, BMBF. The funding of approximately EUR 850,000 supports both companies in establishing a new technology platform for efficient structural characterization of antibody-antigen-complexes.

12 Oct 2010

Experts meet on ESMO Congress to bring new hope to cancer patients

"A congress of records," is how Professor David J. Kerr, President of the European Society for Medical Oncology described the 35th ESMO Congress, at the opening press conference for the biggest medical oncology event in Europe. "We have had record numbers of submitted and accepted abstracts and are expecting a record number of attendees." The ESMO meeting brings together cancer specialists, patients, industry representatives and members of the media. The 35th ESMO Congress takes place at Fiera Milano City, in Milan, Italy, from 8 to 12 October 2010.

8 Oct 2010

Medical researchers take the next step in personalized medicine

Prescription drugs and their dosages may be standardized, but not every patient reacts to a medicine in the same way. The personal genetic characteristics of individuals and populations can explain why a specific prescription successfully treats one patient and not another, so medical researchers are adopting the new approach called "personalized medicine" and a Tel Aviv University lab is leading the way.

8 Oct 2010

BioNJ creates special diagnostics committee to focus on personalized medicine

The strength of New Jersey's life sciences community and its unique ability to contribute to one of medicine's fastest growing areas—personalized medicine—has prompted BioNJ, the voice of the biotechnology industry in New Jersey, to create a special Diagnostics Committee.

7 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

4 Oct 2010

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

A researcher from the biomedical engineering department operated by Georgia Tech and Emory University has received a $1.5 million NIH Director's New Innovator Award to support a project aimed at reducing the incidence of stroke in children with sickle cell disease. Manu Platt, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering, will use the National Institutes of Health (NIH) funding to develop models for identifying which children with the disease are at risk for stroke.

1 Oct 2010

New genetic screening program to reduce risk associated with Plavix

Beginning this month, all patients undergoing cardiac catheterization at Vanderbilt University Medical Center will be tested for a genetic variation that can affect their response to Plavix, the most commonly prescribed clot-preventing drug for heart patients and one of the most commonly prescribed drugs worldwide.

29 Sep 2010

Study: Genetic ancestry has no influence on how African-Americans with asthma respond to medication

Genetic ancestry has no discernible influence on how African American patients with asthma respond to medication, according to a Henry Ford Hospital study.

28 Sep 2010

Progenika receives CE Mark approval to market LPLchip in Europe

Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene.

27 Sep 2010

Researchers synthesize molecule to block abnormal protein in cancer cells

In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.

27 Sep 2010

New analytical technique to improve personalized medicine

In the future, even before the start of the treatment, physicians will be able to establish how patient's blood binds a given medicine and what doze should be applied in order to obtain the concentration in the body that would be optimal for the treatment. A new simple method of analysis of chemical reactions proceeding in solutions has been developed in the Institute of Physical Chemistry of the Polish Academy of Sciences.

23 Sep 2010

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.

23 Sep 2010

Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

Ninth Annual World Conference of the Human Proteome Organization -- Agilent Technologies Inc. (NYSE:A) today announced that its collaboration with the Institute for Systems Biology (ISB) and the Swiss Federal Institute of Technology (ETH Zurich) for the mapping of the complete human proteome by mass spectrometry is entering its second phase.

22 Sep 2010

Hastings Center Report examines ethical controversies over use of personalized medicine

As government support for personalized medicine grows, a consumer advocate, a patient, and bioethicists explore ethical controversies. Direct-to-consumer genetic tests, privacy, targeted cancer therapies, and Henrietta Lacks are among topics in a special issue of the Hastings center Report

18 Sep 2010

Precision Medicine News and Research

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

Sirius collaborates with Golden Helix to advance diagnostic pipeline

NCI rates Abramson Cancer Center as 'exceptional'

STOA Panel schedules hearing on EU's health-related research infrastructures

MorphoSys and Proteros Biostructures receive research grant to develop new technology platform for structure-based engineering of antibodies

Experts meet on ESMO Congress to bring new hope to cancer patients

Medical researchers take the next step in personalized medicine

BioNJ creates special diagnostics committee to focus on personalized medicine

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

New genetic screening program to reduce risk associated with Plavix

Study: Genetic ancestry has no influence on how African-Americans with asthma respond to medication

Progenika receives CE Mark approval to market LPLchip in Europe

Researchers synthesize molecule to block abnormal protein in cancer cells

New analytical technique to improve personalized medicine

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Agilent, ISB and ETH Zurich enter second phase of mapping complete human proteome

Hastings Center Report examines ethical controversies over use of personalized medicine

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News